Dentsply Sirona suspends Byte aligner sales after FDA consult; Q3 rev ~$951M, impairment up to $550M

DENTSPLY SIRONA Inc.

Voluntarily suspends sale/marketing of Byte aligners and impression kits in consultation with FDA.
Byte represents ~5% of annual revenue; suspension expected to materially impact operations.
Prelim Q3 net sales ~$951M; adjusted EPS guided $0.49-$0.51 (non-GAAP).
Expects $450-$550M non-cash goodwill impairment (net of tax) for Orthodontic Aligner and Implant reporting units.
Q3 sales benefited by ~$20M shift of distributor orders from Q4 due to ERP implementation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.